Skip to main content

Advertisement

Table 3 Resistance to therapy for chronic Hepatitis B treatment [1116]

From: Cost-effectiveness analysis of oral anti-viral drugs used for treatment of chronic hepatitis B in Turkey

Years 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Resistance
 TDF 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
 ETV 0.2 0.3 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
 3TC 6.7 11.3 21.0 11.3 6.4 3.2 1.6 0.8 0.4 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
 LtD/Hbe− 1.1 2.2 4.1 2.2 1.2 0.6 0.3 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
 LtD/Hbe+ 5.0 6.3 11.6 6.3 3.5 1.8 0.9 0.4 0.2 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Cumulative resistance
 TDF 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
 ETV 0.2 0.5 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2
 3TC 6.7 18.0 39.0 50.3 56.7 59.9 61.5 62.3 62.7 62.9 63.0 63.1 63.1 63.1 63.1 63.1 63.1 63.1 63.1
 LtD/Hbe− 1.1 3.3 7.4 9.6 10.8 11.4 11.8 11.9 12.0 12.0 12.1 12.1 12.1 12.1 12.1 12.1 12.1 12.1 12.1
 LtD/Hbe + 5.0 11.3 22.9 29.1 32.7 34.4 35.3 35.8 36.0 36.1 36.1 36.2 36.2 36.2 36.2 36.2 36.2 36.2 36.2
  1. Values are expressed as %